Wegovy (Semaglutide 2.4 mg) Vomiting: When It Doesn't Go Away

The Wegovy label pools three placebo-controlled trials: 2,116 adults on 2.4 mg weekly for up to 68 weeks and 1,261 on placebo [1]. Vomiting occurred in 24% versus 6%, nausea in 44% versus 16%, diarrhea in 30% versus 16% and constipation in 24% versus 11% [1]. Counting any gastrointestinal reaction, 73% versus 47% [1]. The label also separates severity: severe gastrointestinal reactions occurred in 4.1% of people on Wegovy injection versus 0.9% on placebo [1].

Stopping treatment is less common than those raw rates suggest. In the pooled trials, 6.8% of participants on 2.4 mg stopped for an adverse reaction versus 3.2% on placebo, and vomiting specifically led to stopping in 1.2% versus 0% [1]. In STEP 1, the 1,961-person trial behind the weight-loss indication, 4.5% of participants on semaglutide stopped for a gastrointestinal event versus 0.8% on placebo [2].

Vomiting was more frequent at the higher dose. In two 72-week trials that compared 7.2 mg with 2.4 mg and placebo, vomiting was reported by 22% on 7.2 mg, 16% on 2.4 mg and 6% on placebo [1]. In the adolescent trial (ages 12 and older, 133 on semaglutide and 67 on placebo), vomiting was 36% versus 10% [1].

What the label says about gastric emptying and dose steps

Wegovy is a GLP-1 receptor agonist, and the label states that it delays gastric emptying [1]. Wegovy starts at 0.25 mg once weekly for 4 weeks and increases every 4 weeks, reaching a maintenance dose of 1.7 mg or 2.4 mg from week 17; the label says this schedule is intended to minimize gastrointestinal adverse reactions [1].

How long does vomiting last?

The label does not say. Its adverse reaction tables report the share of people who vomited at some point across up to 68 weeks (24% versus 6%), not how long a single episode lasted or how quickly it settled after a dose increase [1].

What the label does give is a plan for the next dose. For adults using Wegovy for weight reduction, the maintenance dose is 2.4 mg weekly (recommended) or 1.7 mg weekly, and the label says to consider treatment response and tolerability when choosing [1]. During dose escalation, the label says to consider delaying escalation for 4 weeks if a dose is not tolerated [1]. It names no antiemetic medicine for vomiting [1].

How long does the drug stay in the body?

Semaglutide is cleared slowly. Its elimination half-life is about 1 week, and the label states that the drug remains in the body for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection [1].

Label warnings that can involve persistent vomiting

Acute pancreatitis. The label says pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has occurred with GLP-1 receptor agonists including Wegovy. The symptom it names is persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and the label says to discontinue Wegovy if pancreatitis is suspected [1]. Confirmed pancreatitis occurred in 4 Wegovy-treated adults (0.2 cases per 100 patient-years) versus 1 on placebo [1].

Kidney injury from fluid loss. Acute kidney injury due to volume depletion is a labeled warning. In the Wegovy trials it occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, often after gastrointestinal fluid loss. The label says to monitor kidney function in patients reporting reactions that could lead to volume depletion [1].

Gastroparesis, ileus and obstruction. The label says Wegovy is not recommended in patients with severe gastroparesis, as part of its severe gastrointestinal warning. It does not state that semaglutide causes gastroparesis. Ileus, intestinal obstruction and severe constipation with fecal impaction appear in the label's postmarketing reports, and the label notes that frequency cannot be estimated from voluntary reports [1].